Welcome to The Division of Pediatric Hematology-Oncology and Pediatric Bone Marrow Transplant. Our team, consisting of Physicians, Nurses, Nurse Practitioners, Hem-Onc Fellows in -training, Clinical Pharmacists, Child Life, Social Workers and Dieticians, work together to provide state-of-the-art, personalized, and family-centered care for children and young adults with blood disorders and cancer.
Our program is renowned for our expertise in cancers like leukemia, lymphoma, and solid tumors including neuroblastoma, sarcoma and brain tumors which affect children, adolescents, and young adults. We also have multi-disciplinary clinical programs in blood diseases such as clotting and bleeding disorders, immunohematology, bone marrow failure, anemia, and sickle cell disease. Our team of Bone Marrow Transplantation (BMT) specialists provides our patients and their families with world-class clinical care and a comprehensive plan to meet the need of your child. Our clinics in precision oncology seek to provide the most cutting-edge, personalized assessment of your child’s tumor genetics to guide much more effective and less toxic therapeutic approaches. Our long-term follow-up of childhood cancer survivorship and their families contributes to our Division’s growing community. Patients requiring admission to CS Mott Children’s Hospital are housed in the East Wing of the 7th floor of Mott, which is right next to the outpatient clinic. This wing is a 32 single-bed unit used exclusively for our patients.
Our Division is proud of our many achievements in the fields of basic science research and clinical research which have led to the development of novel therapies for cancer and blood disorders, ultimately contributing to the improved survival and quality of life of these children. We have accomplished basic science researchers amongst our faculty, and we have also partnered with basic science faculty outside our department to expand our impact in research. Our prominent research studies include: understanding the biology of Ewing’s Sarcoma and the biology of diffuse intrinsic pontine glioma (DIPG), understanding the genetic basis of tumor resistance, discovering differences in the tumor genetic profiles of minority children, learning the pathogenesis of leukemia and neuroblastoma, as well as developing immune therapy for leukemias, lymphomas, and solid tumors. In addition, we have nationally renowned basic science research programs: discovering the genetic basis for bleeding disorders, developing gene therapy for the treatment of hemophilia, and evaluating the mechanisms of globin switching. Visit the Shavit Lab to learn more about some of this research. Moreover, our clinical research faculty has developed national and international clinical research protocols for the treatments of refractory neuroblastoma, graft-versus-host disease, and adaptive cellular therapy of both leukemia and lymphoma utilizing stem cell transplantation. Our Division enjoys the largest continuing support from the National Institutes of Health (NIH) within Michigan Medicine’s Department of Pediatrics.
We take our responsibility of developing the next generation of leaders very seriously. We currently hold an NIH-supported Hematology Training Grant (T-32), awarded to very few programs in the country, which provides us the opportunity to train the next generation of leaders in the fields of malignant and benign blood disorders. Trainees from our program hold key leadership positions around the country and have successfully established cutting-edge programs, not only at Michigan Medicine, but at other nationally renowned centers as well, and are advancing the field of pediatric hematology and oncology with both their clinical practice and basic science research.
Please feel free to contact us for any questions, concerns, or comments you may have.
Clinic or Patient Related matters: